T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.94B |
| 2 |
Broadcom
AVGO
|
+$2.74B |
| 3 |
Microsoft
MSFT
|
+$2.33B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.47B |
| 5 |
GE Aerospace
GE
|
+$1.27B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.42B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$2.44B |
| 3 |
Apple
AAPL
|
+$2.42B |
| 4 |
FISV
Fiserv Inc
FISV
|
+$2.3B |
| 5 |
Eli Lilly
LLY
|
+$1.78B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.73% |
| 2 | Financials | 12.11% |
| 3 | Healthcare | 10.97% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2976
Future Fuel
FF
$257M
| $55K | ﹤0.01% |
14,047
+3,187
| +29% | +$12.8K |
|
2977
BARK
BARK
$96.3M
| $54K | ﹤0.01% |
3,101
| – | – |
|
2978
DiaMedica Therapeutics
DMAC
$369M
| $53K | ﹤0.01% |
+13,368
| New | +$52.1K |
|
2979
Fate Therapeutics
FATE
$317M
| $53K | ﹤0.01% |
46,855
+8,806
| +23% | +$10.2K |
|
2980
loanDepot
LDI
$298M
| $53K | ﹤0.01% |
+41,283
| New | +$50.5K |
|
2981
Protalix BioTherapeutics
PLX
$211M
| $53K | ﹤0.01% |
+35,278
| New | +$72.2K |
|
2982
Goldgroup Mining Inc.
GORO
$211M
| $52K | ﹤0.01% |
84,700
| – | – |
|
|
LFT
2983
Lument Finance Trust
LFT
$36.5M
| $52K | ﹤0.01% |
+23,084
| New | +$58.1K |
|
2984
PLAYSTUDIOS Inc
MYPS
$67.3M
| $52K | ﹤0.01% |
39,525
| – | – |
|
2985
Zevia
ZVIA
$104M
| $52K | ﹤0.01% |
+15,945
| New | +$42K |
|
2986
Aemetis
AMTX
$126M
| $51K | ﹤0.01% |
20,463
-17,553
| -46% | -$29.7K |
|
2987
Rafael Holdings
RFL
$103M
| $51K | ﹤0.01% |
29,321
-410
| -1% | -$668 |
|
|
AIRJ
2988
Montana Technologies Corp
AIRJ
$458M
| $51K | ﹤0.01% |
+10,871
| New | +$50K |
|
2989
Protara Therapeutics
TARA
$230M
| $50K | ﹤0.01% |
+16,353
| New | +$56.4K |
|
|
TEAD
2990
Teads Holding Co
TEAD
$64.4M
| $49K | ﹤0.01% |
19,620
+3,087
| +19% | +$9.34K |
|
2991
Kartoon Studios
TOON
$38.7M
| $49K | ﹤0.01% |
65,355
-885
| -1% | -$610 |
|
2992
Zentalis Pharmaceuticals
ZNTL
$307M
| $49K | ﹤0.01% |
41,454
-28,231
| -41% | -$37.2K |
|
|
ILLR
2993
Triller Group Inc
ILLR
$21.1M
| $49K | ﹤0.01% |
+5,249
| New | +$46.3K |
|
2994
Karyopharm Therapeutics
KPTI
$46M
| $47K | ﹤0.01% |
+10,886
| New | +$53.4K |
|
2995
Rackspace Technology
RXT
$1.18B
| $47K | ﹤0.01% |
36,459
+8,521
| +30% | +$11.1K |
|
2996
Holley
HLLY
$384M
| $45K | ﹤0.01% |
22,221
+1,974
| +10% | +$4.19K |
|
2997
Coherus Oncology
CHRS
$181M
| $43K | ﹤0.01% |
58,482
+10,329
| +21% | +$8.92K |
|
2998
Lexeo Therapeutics
LXEO
$400M
| $42K | ﹤0.01% |
10,425
| – | – |
|
2999
Nkarta
NKTX
$171M
| $42K | ﹤0.01% |
25,196
+1,238
| +5% | +$2.27K |
|
3000
Tenaya Therapeutics
TNYA
$171M
| $42K | ﹤0.01% |
67,582
-21,988
| -25% | -$11.2K |
|
Similar funds
T. Rowe Price Associates's Q2 2025 Portfolio in Review
As of Q2 2025, T. Rowe Price Associates held 3,193 positions worth $883B, up 8.8% from $812B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2025 filing shows 153 new, 2,010 increased, 803 reduced and 136 closed positions. Its largest new stake was Ralliant Corp: 4,667,638 shares worth $226M. The largest sale was Amazon, an estimated $3.42B.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 30% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q2 2025 buy was Ralliant Corp: 4,667,638 shares worth $226M.
- T. Rowe Price Associates added most to NVIDIA in Q2 2025, an estimated $3.94B increase.
- T. Rowe Price Associates's biggest Q2 2025 reduction was Amazon, cutting an estimated $3.42B.
- T. Rowe Price Associates fully exited US Steel in Q2 2025, selling an estimated $146M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $883B portfolio in Q2 2025.
- T. Rowe Price Associates opened 153 new positions and closed 136 in Q2 2025.
- T. Rowe Price Associates's portfolio value rose 8.8% quarter-over-quarter to $883B.
Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.